BGLC vs PATH · rev $9.5M vs P/E 19, rev $1.61B
BioNexus Gene Lab Corp Common stock (BGLC) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported BGLC revenue for 2024-12-31 was $9.5M. Net income was $1.6M. Revenue was down 2.7% from 2023-12-31 to 2024-12-31. BGLC currently screens at market cap $6.1M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
BGLC currently screens at market cap $6.1M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the BGLC and PATH stock pages for the full models.
Not investment advice.